Kaléo is a new type of pharmaceutical company, dedicated to building innovative solutions for serious and life-threatening medical conditions. We believe patients and caregivers are the experts on how their medical condition impacts their lives and are an integral part of our product development process.
- Ron Gunn, President and CEO
- Tom Assalley, Vice President, Market Access
- Neil Bajaj, Vice President, Strategy
- Allison Bridges, General Manager, Allergy and Pediatrics
- Elvira Cashel, Vice President, Human Resources
- Kevin Espinoza, Chief Compliance Officer
- Mark Herzog, Vice President, Corporate Affairs
- Glen Kelley, Vice President, Regulatory Affairs
- Chris Schools, Chief Financial Officer
- Todd Lambert, Vice President, Sales and Training
- Chuck Nicholls, Vice President, Global Supply Chain and Manufacturing
- Ann Rademacher, Vice President, Quality Assurance
- Matthew Simmons, Vice President, Finance and Analytics
- Eric Edwards, MD, PhD
- Evan Edwards
Patients and families would be without a champion developing innovative healthcare solutions that empower them to confidently live fuller, bolder lives.
A world in which all people have access to the innovative healthcare products and solutions that empower each of them to live fuller, bolder lives.
To invent, manufacture and commercialize life-transforming products that empower patients and families to live fuller, bolder lives.
Develop innovative solutions that support the healthcare provider-patient relationship, unleashing access to life-transforming products.
It’s no coincidence that Kaléo so strongly believes in patient-inspired design through true collaboration between our experts and the people who use our products.
When our founders, twin brothers Eric and Evan Edwards, were young children, they were diagnosed with life-threatening allergies to a wide range of items, including peanuts, tree nuts, seafood and eggs, they were taught to carry a dose of epinephrine with them at all times. Eric and Evan decided to develop another option for patients like themselves and, in their late teens, conceived a new epinephrine delivery system. This led to the formation of Intelliject, later renamed Kaléo.